Pharma BD Deal Intelligence
Mylan's India API bet gave it low-cost manufacturing scale but also chronic FDA quality problems, culminating in Viatris divesting the entire business at a loss in 2024 — a 17-year experiment ultimately deemed non-core.
Full analysis, sources & comparables →The acquisition lets Mylan 'establish a global platform and expand its dosage forms and therapeutic categories' while deepening 'vertical integration and…
Mylan to acquire up to 71.5% controlling interest in Matrix Laboratories for Rs. 306 per share (~$736 million), framed as an extremely complementary…
The Matrix transaction was the largest-ever takeover in the Indian pharma industry at the time and was credited with helping move Mylan from the third-largest…
Source summaries from our enrichment pipeline; follow links for originals.
All 7 sources with sentiment breakdown →
Mylan announces controlling stake acquisition of India's Matrix Laboratories (API supplier). Initial agreement July 2005; $736M total deal completed Jan 2007 for 71.5% stake.
Mylan's India API bet gave it low-cost manufacturing scale but also chronic FDA quality problems, culminating in Viatris divesting the entire business at a loss in 2024 — a 17-year experiment ultimately deemed non-core.
Assessment window: 15yr post-close.
| Deal | Year | Value | Outcome |
|---|---|---|---|
| Mylan Laboratories Inc. / Matrix Laboratories Limited (this deal) | 2005 | $736M | 39 |
| Mylan Laboratories Inc. / Merck Generics (Merck KGaA) | 2007 | $6.7B | 81 |
| Mylan Laboratories Inc. / Matrix Laboratories Limited | 2006 | $736M | 66 |
| Mylan Laboratories Inc. / King Pharmaceuticals Inc. | 2004 | $4.0B | — |
| AstraZeneca PLC / KuDOS Pharmaceuticals Limited | 2005 | $210M | 98 |
| Yamanouchi Pharmaceutical / Fujisawa Pharmaceutical Co. Ltd. | 2005 | — | 92 |
| Sankyo Co., Ltd. / Daiichi Pharmaceutical Co., Ltd. | 2005 | $8.0B | 92 |